Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $103343.0.

  • China Pharma Holdings' Other Operating Expenses fell 2226.75% to $103343.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $467982.0, marking a year-over-year decrease of 2536.11%. This contributed to the annual value of $534526.0 for FY2024, which is 3008.81% down from last year.
  • Per China Pharma Holdings' latest filing, its Other Operating Expenses stood at $103343.0 for Q3 2025, which was down 2226.75% from $103324.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Other Operating Expenses high stood at $440734.0 for Q2 2021, and its period low was $85788.0 during Q1 2025.
  • Moreover, its 5-year median value for Other Operating Expenses was $174040.0 (2022), whereas its average is $200383.1.
  • As far as peak fluctuations go, China Pharma Holdings' Other Operating Expenses plummeted by 7875.37% in 2021, and later skyrocketed by 3005.38% in 2022.
  • China Pharma Holdings' Other Operating Expenses (Quarter) stood at $286280.0 in 2021, then increased by 23.75% to $354261.0 in 2022, then decreased by 24.35% to $267996.0 in 2023, then tumbled by 34.5% to $175527.0 in 2024, then crashed by 41.12% to $103343.0 in 2025.
  • Its Other Operating Expenses stands at $103343.0 for Q3 2025, versus $103324.0 for Q2 2025 and $85788.0 for Q1 2025.